Investment in Equity Securities, at Fair Value and Long-term Investments (Tables)

9 Months Ended

Sep. 30, 2022

Investment in Equity Securities, at Fair Value and Long-term Investments

Schedule of investment

				Gross
(In thousands)				unrealized		Aggregate fair
September 30, 2022	Classification	Cost		gains /(losses)		value
MaxCyte - equity interest	Investment	$	—	$	2,453	$	2,453
BioInvent - equity interest	Investment	$	4,337	$	(481)	$	3,856
Total						$	6,309
				Gross
(In thousands)				unrealized		Aggregate fair
December 31, 2021	Classification	Cost		gains		value
MaxCyte - equity interest	Investment	$	—	$	3,866	$	3,866
BioInvent - equity interest	Investment	$	5,661	$	341	$	6,002
Total						$	9,868

Schedule of components of long-term investments

Long-term investments as of September 30, 2022 and December 31, 2021 consisted of the following:

					Gross		Foreign
			Gross		unrealized		currency
September 30, 2022			unrealized		losses (including		translation		Aggregate
(In thousands)	Cost		gains		impairment)		adjustment		fair value
Available-for-sale debt securities:
Alesta Therapeutics B.V. - convertible loan	$	261	$	15	$	—	$	—	$	276
Securities measured at fair value:
BioInvent International AB - warrants		656		—		(194)		—		462
Cleave Therapeutics, Inc. - convertible loan		5,500		458		—		—		5,958
Equity securities without readily determinable fair value:
Alesta Therapeutics B.V. - equity interests		2,250		—		(865)		—		1,385
Juventas Biotechnology (Tianjin) Co., Ltd. - equity interests		23,500		6,958		—		(1,569)		28,889
Juventas Biotechnology (Tianjin) Co., Ltd. - put option		491		—		(521)		30		—
Prepayment for investment:
Precision Autoimmune Therapeutics Co., Ltd - equity interests		2,962		—		—		(152)		2,810
Total	$	35,620	$	7,431	$	(1,580)	$	(1,691)	$	39,780

					Gross		Foreign
			Gross		unrealized		currency
December 31, 2021			unrealized		losses (including		translation		Aggregate
(In thousands)	Cost		gains		impairment)		adjustment		fair value
Available-for-sale debt securities:
Alesta Therapeutics B.V. - convertible loan	$	261	$	7	$	—	$	—	$	268
Securities measured at fair value:
BioInvent International AB - warrants		656		—		(65)		—		591
Cleave Therapeutics, Inc. - convertible loan		5,500		76		—		—		5,576
Equity securities without readily determinable fair value:
Alesta Therapeutics B.V. - equity interests		2,250		—		(865)		—		1,385
Juventas Biotechnology (Tianjin) Co., Ltd. - equity interests		23,500		6,958		—		1,850		32,308
Juventas Biotechnology (Tianjin) Co., Ltd. - put option		491		—		(521)		30		—
Total	$	32,658	$	7,041	$	(1,451)	$	1,880	$	40,128